These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 2037710)

  • 21. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of multiple-dose cefprozil and comparison with cefaclor.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1198-203. PubMed ID: 2393281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
    Lien CA; Schmith VD; Embree PB; Belmont MR; Wargin WA; Savarese JJ
    Anesthesiology; 1994 Jun; 80(6):1296-302. PubMed ID: 8010476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis.
    Sica DA; Marino MR; Hammett JL; Ferreira I; Gehr TW; Ford NF
    Clin Pharmacol Ther; 1997 Dec; 62(6):610-8. PubMed ID: 9433389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology and pharmacokinetics of cefprozil.
    Barriere SL
    Clin Infect Dis; 1992 Jun; 14 Suppl 2():S184-8; discussion S195-6. PubMed ID: 1617036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency.
    Patel IH; Bornemann LD; Brocks VM; Fang LS; Tolkoff-Rubin NE; Rubin RH
    Antimicrob Agents Chemother; 1985 Jul; 28(1):46-50. PubMed ID: 4037777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients.
    Aparicio M; Dratwa M; el Esper N; Fillastre JP; Levaltier B; Lins R; Meyrier A; Mignon F; Ryckelynck JP; Sennesael J
    Am J Cardiol; 1994 Dec; 74(13):43A-50A. PubMed ID: 7998585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of cefodizime in patients with various degrees of renal failure.
    Loffreda A; Lampa E; Lucarelli C; Amorena M; Contaldi C; Calderaro V; Rossi F
    Chemotherapy; 1999; 45(1):1-7. PubMed ID: 9876203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis.
    Foote EF; Look ZM; Giles P; Keane WF; Halstenson CE
    Am J Kidney Dis; 1995 Mar; 25(3):420-5. PubMed ID: 7872319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
    Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
    Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
    Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of cefpodoxime proxetil in hemodialysis patients.
    Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    J Clin Pharmacol; 1992 Nov; 32(11):1038-44. PubMed ID: 1474165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
    Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral flecainide pharmacokinetics in patients with impaired renal function.
    Forland SC; Burgess E; Blair AD; Cutler RE; Kvam DC; Weeks CE; Fox JM; Conard GJ
    J Clin Pharmacol; 1988 Mar; 28(3):259-67. PubMed ID: 3129455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
    Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.
    Lode H; Müller C; Borner K; Nord CE; Koeppe P
    Antimicrob Agents Chemother; 1992 Jan; 36(1):144-9. PubMed ID: 1590680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.